Collaboration and license agreements (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of deferred revenue amounts allocated to performance obligations | The following table summarizes the deferred revenue amounts allocated to the Roche Agreement performance obligations (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Transaction Price Allocated To Performance Obligations [Table Text Block] | The following table summarizes the unearned amount of the 2025 Novartis Agreement transaction price allocated to the performance obligations (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||